Impressive Rapid Complete Response on FDG PET/CT to BRAF Inhibitors in a Metastatic Melanoma With Massive Tumor Burden. (February 2022)

• Record Type: Journal Article
• Authors: Abgral, Ronan; Salaun, Pierre-Yves; Sassolas, Bruno
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 2(2022)
• Publication Date: 2022-02
• Subjects: metastatic melanoma -- massive tumor burden -- BRAF inhibitor -- FDG PET/CT -- complete response; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003922
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Recent advances in the development of innovative treatments for MM (metastatic melanoma) significantly improved survival. BRAF inhibitor–targeted therapies are also indicated in stage IV BRAF-mutant melanoma, especially dabrafenib and trametinib in combination. The authors present here an impressive rapid (1 month) complete metabolic response on FDG PET/CT to BRAF inhibitors of an MM with a massive tumor burden estimated at more than 10 kg.